News

A recent study found that recompensation can be a useful clinical endpoint in patients with PBC and decompensated cirrhosis.

Patients with PBC should undergo endoscopic assessments to rule out hidden diseases.

New research explores how type 2 diabetes affects fatty liver, scarring and outcomes in people living with primary biliary cholangitis.

The bile-acid lowering medication cholestyramine may ease PBC itching not just by removing bile acids, but also by improving gut health.

People with PBC had a notable rate of cardiovascular disease, suggesting heart health deserves routine attention alongside liver care.

Genetic analysis showed Crohn’s disease was linked to a higher risk of developing primary biliary cholangitis (PBC).

Vitamin D3 can modulate the immune response to alleviate disease severity in PBC.

UDCA use was associated with significantly lower risks of GI, liver and breast cancers in patients with PBC.

According to a research review, broader autoantibody study could help with more accurate PBC diagnosis and lead to more personalized care.

PPAR agonists reduced biomarkers of liver dysfunction compared to placebo across several clinical trials of patients with PBC.